What retatrutide is
Retatrutide is an investigational injectable medicine from Eli Lilly. It is a triple agonist, meaning it acts on three receptors: GLP-1, GIP, and glucagon. That design separates it from medicines that act on one or two receptors. Retatrutide is not approved by the Food and Drug Administration. It does not have an announced brand name.
Interest is already unusually high. About 550,000 US searches are made for retatrutide each month, even though no approved product exists (source: Semrush via Exploding Topics, November 2026). That attention makes one point especially important: trial results are not the same thing as approval or availability.
What TRIUMPH-1 found
TRIUMPH-1 is the pivotal obesity trial. It included 2,339 participants. Lilly reported average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks. Among patients taking the top dose, 45.3% lost at least 30% of their body weight (source: Lilly trial readout, 2026).
The readout came on May 21, 2026. These are average results from a large study, not a promise about what will happen for any one person. Individual responses can differ, and a qualified health care professional should help put trial averages in context.
The headline result is 30.3% average weight loss at 104 weeks, but retatrutide remains investigational.
What the other trials found
The wider program studied several groups and health conditions. Each result answers a different question, so the figures should not be treated as if they came from one interchangeable population.
- TRIUMPH-2 studied obesity and type 2 diabetes. Lilly reported 20.8% weight loss and an A1C reduction of 1.5%. The readout came July 23, 2026.
- TRIUMPH-3 studied obesity and cardiovascular disease. Lilly reported 22.6% weight loss on July 23, 2026.
- TRIUMPH-4 studied obesity and knee osteoarthritis. Lilly reported 28.7% weight loss in December 2025.
- TRANSCEND-T2D-1 studied diabetes. Lilly reported an A1C reduction of 1.7% to 2.0% and 16.8% weight loss in March 2026.
These findings explain the strong interest, but they do not change the legal status. The FDA still has to review a formal application before the drug can be marketed.
When an FDA decision could happen
Lilly announced on July 23, 2026 that it plans to file a Biologics License Application in the first quarter of 2027. That filing would begin the formal path toward an FDA review.
Standard review math places a possible decision roughly between January and March 2028. A priority review could move the decision into late 2027. A realistic approval range is late 2027 through the middle of 2028. This is an estimate based on review timing, not a confirmed FDA date.
The brand name has not been announced. The name “Bemlayo” has appeared as unconfirmed trademark speculation. It should not be treated as the product name unless Lilly confirms it.
Why you cannot legally buy it now
There is no approved retatrutide product and no legal compounded retatrutide. On October 1, 2026, the FDA stated that retatrutide and cagrilintide cannot be used in compounding under federal law. A website that offers “research” retatrutide is not offering an approved prescription product.
That distinction protects readers from a common marketing trick. An investigational compound sold online is not an early version of a future brand medicine. Weigh In Health does not link to peptide or research chemical sellers.
What may happen after approval
If the FDA approves retatrutide, the product is expected to move through LillyDirect and telehealth platforms that prescribe brand medicines. Approval would also bring an official label. That label would explain approved uses, dosing, warnings, and other information reviewed by the FDA.
Price has not been announced, so any exact retatrutide price today would be invented. Insurance coverage, cash programs, and telehealth fees also cannot be known before the product exists. The responsible move is to wait for an approved label, confirmed price, and legal prescribing channels.
The bottom line
Retatrutide produced notable results across Lilly's trial program. TRIUMPH-1 reported 30.3% average weight loss at 104 weeks (source: Lilly trial readout, 2026). Still, it is investigational, has no confirmed brand name, and cannot legally be compounded. Lilly plans to file in early 2027, with a realistic approval window from late 2027 to the middle of 2028. Until an FDA decision arrives, trial data is the story, not a product anyone can legally buy.